Welcome to our dedicated page for Globus Med SEC filings (Ticker: GMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Globus Medical, Inc. (NYSE: GMED) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a publicly traded musculoskeletal medical device manufacturer, Globus Medical files annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K that describe its operations, risk factors, financial performance, and material events.
Recent Form 8-K filings from Globus Medical have reported preliminary and final net sales and operating results for specific quarters and fiscal years, leadership transitions at the President, Chief Executive Officer, and Chief Financial Officer roles, and other significant corporate developments. These filings often reference earnings press releases furnished as exhibits, which include details on worldwide net sales, U.S. and international performance, non-GAAP financial measures, and guidance for future periods.
Through its filings, Globus Medical also explains its use of non-GAAP metrics such as non-GAAP adjusted EBITDA, non-GAAP net income, non-GAAP diluted earnings per share, non-GAAP gross profit, free cash flow, constant currency net sales growth, and base business sales excluding contributions from recent acquisitions like Nevro Corp. and its subsidiaries. The company describes how these measures adjust for items such as litigation provisions, amortization of intangibles, merger and acquisition-related costs, restructuring-related costs, certain foreign currency impacts, bargain purchase gains, and specific tax effects.
On this page, Stock Titan pairs Globus Medical’s raw SEC documents with AI-powered summaries that highlight the key points of lengthy filings. Users can quickly see what changed in a new 10-K or 10-Q, how management characterizes performance in 8-K earnings releases, and where non-GAAP adjustments have a material impact. The platform also surfaces real-time updates from EDGAR, helping investors follow new filings as they are posted and review the company’s regulatory history in one place.
Globus Medical Inc: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0% beneficial ownership as disclosed in the filing. The amendment notes an internal realignment of The Vanguard Group and separate reporting by subsidiaries January 12, 2026.
Globus Medical, Inc. reported that Board member John A. DeFord, Ph.D. resigned from the Board of Directors effective immediately on March 23, 2026. The company stated that his decision was not due to any disagreement with the company.
In a related press release, Globus Medical noted that Dr. DeFord will not seek re-election at the Annual Meeting of Stockholders on June 3, 2026, and highlighted his contributions, including work during the merger with NuVasive and service on the Nominating and Governance Committee.
Globus Medical EVP and General Counsel Kelly Huller reported option exercises and a share sale involving Class A common stock. On February 25, 2026, Huller exercised stock options for 20,000 shares granted on January 22, 2019, which are described as fully vested.
The option exercise was reported at a price of $43.58 per share, resulting in direct ownership of 20,000 shares of Class A common stock. That same day, Huller sold 20,000 shares of Class A common stock at $94.50 per share, leaving no shares reported as directly owned after the sale.
The filing notes that the sale was carried out under a Rule 10b5-1 trading plan dated November 12, 2025, indicating the sale was pre‑scheduled rather than newly decided at the time of the transaction.
GMED submitted a notice of proposed sale for 20,000 common shares via a cashless stock option exercise dated 02/25/2026. The filing lists shares outstanding 135,253,051 as of 02/25/2026. It also discloses prior sales by Kelly Huller: 10,000 shares on 02/12/2026 for $876,000 and 7,500 shares on 11/25/2025 for $674,619.
Globus Medical, Inc. files its annual report describing a fast-growing musculoskeletal and enabling-technologies business built around spine, orthopedics, biologics, neuromodulation and surgical robotics. The company reported 9 new product launches in 2025 and operates in 65 countries, with international sales representing about 19.4% of 2025 revenue.
Globus highlights two major recent deals: the 2023 stock-for-stock NuVasive merger, which broadened its spine and enabling technologies portfolio, and the 2025 Nevro acquisition, adding the HFX spinal cord stimulation platform for chronic pain in an all-cash transaction at $5.85 per Nevro share. As of February 20, 2026, Class A common shares outstanding totaled 135,253,051.
The report outlines extensive product families in Musculoskeletal Solutions and Enabling Technologies, including ExcelsiusGPS robotics and the expanding Excelsius ecosystem. It also discloses an open July 2024 FDA warning letter tied to complaint-handling and medical device reporting procedures for the ExcelsiusGPS robotic system, though the letter noted no safety concerns or manufacturing issues.
Globus Medical reported a strong finish to 2025 with robust growth in sales, profit and cash flow. Fourth quarter 2025 worldwide net sales were $826.4 million, up 25.7% year over year, while GAAP net income rose to $140.6 million and GAAP diluted EPS reached $1.03, with non-GAAP diluted EPS at $1.28.
For full year 2025, worldwide net sales were $2,938.9 million, up 16.7%, and GAAP net income grew to $537.9 million, driving GAAP diluted EPS of $3.92 and non-GAAP diluted EPS of $3.98. Base business net sales excluding Nevro were $2,645.3 million, up 5.0%, highlighting meaningful contribution from the Nevro acquisition.
Adjusted EBITDA for 2025 was $919.6 million, or 31.3% of net sales, and free cash flow reached $588.8 million. Management reaffirmed 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.40–$4.50, signaling confidence in continued growth and margin expansion.
Globus Medical executive Kelly Huller, EVP, General Counsel and Corporate Secretary, reported an option exercise and share sale. On February 12, 2026, she exercised stock options for 10,000 Class A shares at $45.64 per share, converting a fully vested grant from February 2018.
The same day, she sold 10,000 Class A shares at $87.67 per share in an open-market transaction, leaving her with 0 directly owned shares and 0 remaining options from this grant. The sale was executed under a pre-arranged Rule 10b5-1 trading plan dated November 12, 2025.
An insider of GMED has filed a Form 144 notice to sell 10,000 shares of common stock through Raymond James & Associates on the NYSE. The shares have an aggregate market value of about $876,000 based on the figures disclosed.
The securities were acquired on 02/12/2026 via a cashless option exercise from the issuer, with the same date listed as the payment date. Over the prior three months, the same seller, Kelly Huller, sold 7,500 common shares for gross proceeds of about $674,620.
Globus Medical director Leslie V. Norwalk received a grant of 15,000 stock options for Class A common stock. The options carry an exercise price of $94.15 per share and were granted as a derivative equity award.
According to the filing, these options were granted on January 21, 2026, will vest on January 1, 2027, and expire on January 21, 2036. After this grant, Norwalk beneficially owns 15,000 derivative securities directly, reflecting a standard director compensation award rather than an open-market transaction.
Globus Medical Inc. reported a new stock option grant to its President and CEO, Keith W. Pfeil. On January 21, 2026, Pfeil received stock options giving him the right to buy 100,000 shares of Class A common stock at an exercise price of $94.15 per share. The options were granted at no cost to him as compensation and expire on January 21, 2036.
The award vests over four years, with one-quarter of the options vesting on January 1, 2027 and the remaining options vesting in equal monthly installments (1/48 of the total) each month thereafter. All 100,000 options are reported as held directly by Pfeil following this grant.